Search PubMed⌕ Search

Biomedical subjects

G Bertolini

Publications and source records attributed to G Bertolini.

11 recordsLinked to original sources
PubMed1991

Vascular protection of lacidipine in salt-loaded Dahl-S rats at nonsustained antihypertensive doses.

The aim of this study was to characterize the antihypertensive and vasoprotective properties of lacidipine in salt-loaded Dahl-S rats, a suitable animal model of malignant hypertension. After 9 weeks of a high (8%) sodium chloride (NaCl) diet, 80% of the untreated Dahl-S rats died (20% survival rate) whereas a 100% survival rate was observed with chronic treatment with lacidipine at doses of 0.1 (equivalent to the recommended dose in humans), 0.3, 1, and 10 mg/kg once daily by gastric gavage. The most interesting results included the following: (a) Only the highest dose tested (10 mg/kg once daily) was able to control the increase in blood pressure, which was measured 24 h after the preceding administration of drug, yet a 100% survival rate was maintained. (b) There appeared to be prevention of brain lesions, which is very likely the cause of the survival of all of the lacidipine-treated rats in this study. (c) A clear dose-related vascular protection was observed in other tissues. In conclusion, lacidipine protects against the vascular damage and concomitant increase in mortality of salt-loaded Dahl-S rats even at doses that do not adequately control the development of hypertension.

Administration, Oral↗
PubMed1987

[A new method for the determination of the multiple molecular forms of gamma-glutamyltransferases after electrophoresis on cellulose acetate. Preliminary data].

What is described is a new, sensitive, simple and precise method for the visualization of the multiple molecular forms of the gamma-glutamyltransferase by means of electrophoresis on cellulose acetate in parallel with the serum protein pattern. The isoenzymatic pattern in 100 cases with a normal catalytic activity was mainly represented by two bands, one in the alpha 1 region and one in the alpha 2. Also examined was the serum of 103 cases having various hepatic biliary pathologies and a catalytic activity out of the reference interval, in an attempt to evaluate the diagnostic usefulness of the various isoenzyme patterns.

Electrophoresis↗
PubMed1985

[Renal tolerance of an incremental dosage regimen of anturan in the aged with altered renal function]].

The aim of the study was to investigate renal tolerability of a flexible increasing dose-schedule of anturan (E), dependent on basal serum creatinine values. 12 male cardiovascular elderly patients (mean age: 75 years; SD: 5.5 years) suffering from mild chronic renal failure (serum creatinine between 2.00 and 4.00 mg/100 ml) entered an open study of 2-month duration. Starting dosage was 200 mg per day; daily dosage was then increased every 4 days of 200 mg, or kept constant for another 4 days, according to each patient's renal function, up to 800 mg per day. All the patients reached the maintenance dosage of 800 mg/day in 12 days, because renal function didn't worsen. Two patients were withdrawn: one at the end of the 1st month of E therapy because of exitus due to myeloma, the other one at the 24th day of E therapy for serum creatinine increase, possibly related to ongoing therapy. Creatinine clearance significantly increased, serum creatinine and uric acid significantly decreased at the end of E therapy. The other biochemical examinations didn't change and no patient complained of any undesired effect during the whole study. The obtained results seem to prove that anturan, if an incremental dose-schedule is followed at the beginning of therapy is well tolerated even in elderly azotemic patients.

Aged↗